STAT+: Pharmalittle: Most Americans support Medicare drug price negotiations; Moderna refuses to share its Covid-19 vaccine secret sauce
Hello, everyone, and nice to see you again after an extended weekend break, which included…
Category: STAT+
STAT+: Some Dana-Farber Cancer Institute trustees stood to profit from their philanthropic role
The trustees of the world-renowned Dana-Farber Cancer Institute serve a vital role. They hire the…
STAT+: 5 health tech startups working to address chronic pain without opioids
As the country grapples with both the Covid-19 pandemic and the ongoing opioid crisis, chronic…
STAT+: Devoted Health raises a record $1.2 billion to expand care for older Americans
It is an extraordinary amount of money at an extraordinary time. Devoted Health, a startup…
STAT+: Pharmalittle: How COVAX failed on its promise to vaccinate the world; White House close to picking FDA nominee
Good morning, everyone. Damian Garde here, filling in for Ed Silverman on a sunny morning…
STAT+: Relay Therapeutics touts data on bile cancer drug
Relay Therapeutics will present data at a medical meeting Friday that give investors and oncologists…
.jpg)
STAT+: FDA halts Allogene blood cancer trials after patient found to have ‘chromosomal abnormality’
Allogene Therapeutics said Thursday that the Food and Drug Administration had placed a hold on…
.jpg)
STAT+: AbbVie loses a lawsuit over Humira trade secrets it claimed were stolen
In a setback to AbbVie (ABBV), a U.S. federal court judge dismissed a lawsuit in…
STAT+: Europe’s largest clinical trial sponsors are getting better at reporting results
More than two dozen of the largest universities and hospitals in Europe have shown a…
STAT+: Moderna plans a vaccine plant in Africa, but critics say the move isn’t enough to ensure access
Amid intense concern that low-income countries lack access to Covid-19 vaccines, Moderna (MRNA) announced plans…
STAT+: Pharmalittle: White House and Moderna battle over global vaccine donations; Pfizer seeks FDA OK for kids to get its Covid shot
Rise and shine, everyone, another busy day is on the way. This morning is getting…
STAT+: Disappointing tumor responses, more side effects, seen with latest Amgen KRAS combination studies
Combining Amgen’s KRAS-blocking cancer drug Lumakras with other targeted medicines led to higher rates of…
STAT+: Backed with $500 million, a startup aims to rethink psychiatric drug development
For more than a decade, psychiatry has been a graveyard for new medicines. While in…
STAT+: Here’s who might replace Francis Collins as NIH director
WASHINGTON — Almost as soon as Francis Collins announced that he’ll soon step down as…
STAT+: Older Americans bore the brunt of antibiotic-resistant infections, study finds
Older Americans were disproportionately affected by several different types of infection for which antibiotics were…
STAT+: Northwest Bio marks ignominious anniversary of brain tumor study delay with silence
Northwest Biotherapeutics has buried data from its completed brain cancer clinical trial for so long…
STAT+: Pharmalittle: Henrietta Lacks estate plans to sue more companies; Sweden halts Moderna Covid shot for people 30 and younger
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
Lawyers for Henrietta Lacks estate say more companies to be sued over use of her cells
Trillions of her cells have played a pivotal role in medical research for the past…
STAT+: AstraZeneca to pay $560,000 to settle claims of discriminating against women sales reps
Following a federal investigation, AstraZeneca (AZN) has agreed to pay $560,000 to hundreds of sales…
STAT+: Pharmalittle: Francis Collins to step down as NIH director; Research confirms decline in Pfizer vaccine protection against ‘breakthrough’ infection
Good morning, everyone, and how are you today? Gray skies are hovering over the Pharmalot…
STAT+: Carbon Health pushes further into home care with remote monitoring purchase
On a buying streak, hybrid care company Carbon Health on Tuesday purchased Alertive Healthcare, a…
STAT+: Vedanta touts positive new data for its C. diff microbiome therapeutic — but is it too late?
Vedanta Biosciences is touting positive new Phase 2 results for a microbe-based treatment for C….
STAT+: First they targeted generic drugs. Now a group of hospitals wants to build a better digital health marketplace
It’s one of the biggest market failures in modern medicine. The lack of a widely…
STAT+: The Merck Covid-19 pill may be a game changer, but questions are already being raised about cost
Behind the unvarnished enthusiasm over an experimental Covid-19 pill, questions are emerging about the cost…
STAT+: Pharmalittle: J&J to seek emergency use of Covid-19 vaccine booster; Pfizer loses legal battle over Medicare co-pay programs
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: The health tech tracker for the fourth quarter: the decisive industry events to watch
Winter may be coming (again), but the digital health sector remains red-hot. Fueled by fresh…
STAT+: The biotech scorecard for the fourth quarter: 19 stock-moving events to watch
The year is almost over! Here is STAT’s biotech scorecard, our regular ledger of stock-moving…
STAT+: Inside the downfall of longevity crusader Aubrey de Grey — and the cult of personality that concealed a pattern of harassment
“You’ve been a bad boy,” Moses Znaimer, the bespectacled media mogul often referred to as…
STAT+: Pfizer loses a lawsuit alleging the U.S. illegally limits use of patient copay assistance programs
In a setback to the pharmaceutical industry, a federal judge ruled that programs Pfizer (PFE)…
STAT+: Three generic drug makers to pay $450 million to settle criminal price fixing charges
Three generic drug makers agreed to pay nearly $450 million to resolve civil allegations that…
STAT+: Prosecutors allege two individuals preyed on those searching for addiction recovery help
Two men were indicted this week for allegedly running a scam in which they preyed…
STAT+: Pharmalittle: Merck’s Covid-19 pill reduced hospitalizations in a study; Dems start scaling back drug-pricing plans
And so, another working week will soon draw to a close. Not a moment too…
STAT+: In the ‘fail fast’ world of biotech, ‘offboarding’ is just as important as onboarding
In today’s biotech job market — where competition for people with in-demand experience is fiercer…
STAT+: Why the medical AI company Dascena hopes hard evidence will separate it from its rivals
Think of it as digital health’s chicken and egg problem. Which comes first: national distribution…
STAT+: Biden administration favors insurers over doctors in controversial new surprise billing regulations
WASHINGTON — The Biden administration on Thursday sided with insurers over physicians and other health…
STAT+: Genetic information can be messy. Mapping proteins could offer a clearer view of what’s driving cancer
Scientists have unveiled new maps of the protein networks underlying different types of cancer, offering…
STAT+: Key Senate committee considers a carveout for small biotech companies in drug pricing reforms
WASHINGTON — A key Senate panel is seriously considering a new policy that would soften…
STAT+: Appeals court rules FDA ‘arbitrarily and capriciously’ approved a rare disease drug
In a closely watched battle over regulatory decision-making, a federal appeals court ruled the U.S….
STAT+: With $11 billion Acceleron deal, new Merck CEO hopes to convince investors there is a lot more to the biopharma giant
Merck will continue to search out more acquisitions after its $11 billion purchase of biotech…
STAT+: Pharmalittle: House panel OKs bills to halt pharma practices that raise prices; Merck to buy Acceleron for $11.5 billion
Rise and shine, everyone, another busy day is on the way. This morning is getting…
STAT+: Pharmalittle: Run on ivermectin tablets leaves less for livestock; Pfizer Covid-19 shot for kids may not come until November
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT+: Editas CRISPR treatment improved vision for one patient, but not others, early data show
An experimental CRISPR-based treatment from Editas Medicine led to meaningful improvements in the functional vision…
STAT+: As lawsuits mounted, Purdue cultivated conversations with a controversial addiction policy group
Over several months in 2017, a top Purdue Pharma executive and the head of the…
STAT+: Lilly cuts the wholesale price on some insulin products, but impact is likely to be limited
Eli Lilly (LLY) announced plans to lower the wholesale price of certain insulin products by…
STAT+: FDA tells drug makers to redo studies run by two contract research firms due to data integrity issues
In a rare move, the U.S. Food and Drug Administration has notified an untold number…
STAT+: Pharmalittle: Sanofi ends work on mRNA Covid-19 vaccine; Biogen seeks fast FDA approval of another Alzheimer’s drug
Top of the morning to you. And a fine one it is. Crystal clear blue…
STAT+: Graduate students launch an entrepreneurship program to bring new faces to biotech
A group of graduate students is expanding a Boston-based biotech entrepreneurship program across the country,…
STAT+: Biogen, Eisai seek fast approval for second Alzheimer’s drug, relying on relaxed FDA standard
Biogen and its Japanese partner Eisai announced Monday evening the start of an application process…
STAT+: Big business lobbies bitterly divided over drug pricing reform
WASHINGTON — Groups representing companies like Apple, Tesla, and Boeing are clashing with Washington’s wealthiest…
STAT+: Inflation and rebates caused wholesale prices on medicines to drop in second quarter
Amid continued political pressure on the pharmaceutical industry, a new analysis finds brand-name drug makers…